[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de Nīmes\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":609},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,42,67,94,121,141,163,189,215,242,265,290,313,342,361,378,399,426,444,466,491,512,531,556,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642801","phase-3-efficacy-in-relapse-prevention-psilocybin-in-alcohol-use-disorder-with-depressive-symptoms-100642801",false,"NCT07638553","Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","ERPPAD","Inclusion Criteria:\n\n* Confirmed DSM-5 diagnosis of severe AUD.\n* Scale BDI-II ((Beck Depression Inventory) ≥14\n* The last drink must have been consumed between day(D) -60 and D -10 at the inclusion visit. The patient must have had at least 1 HDD during the last drinking period NB: The last drinking period before inclusion is defined by the last 4 weeks counted from the last drink.\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study, a clinical trial, or a clinical investigation or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Patient unable to give informed consent.\n* Participants planning to donate sperm within three months of psilocybin administration\n* Positive pregnancy test at inclusion for participants of childbearing age.\n* Patient who is pregnant, breastfeeding, or wishing to become pregnant during participation in the study.\n* Any use of classical psychedelic in the last year\n* Other current substance use disorder (except tobacco)\n* Diagnosed schizophrenic or bipolar disorder\n* High emotional lability (clinician-judged)\n* On antipsychotics treatment that may interfere with psilocybin.\n* Need for monoamine oxidase inhibitor (MAOI) treatment, which may interfere with psilocybin.\n* Severe suicidal ideation (high risk on the Columbia scale)\n* 1st degree family member with a diagnosed psychotic disorder\n* Severe cognitive impairment (clinician-judged)\n* CIWA-AR \\> 8\n* Medical conditions that would preclude safe participation in the trial, for example: seizure disorders; significant impairment of hepatic function; coronary artery disease; history of arrhythmia; Abnormal QT interval prolongation (QTc \\> 470 ms for women and \\>450 ms for men); heart failure; uncontrolled hypertension (greater than 165\u002F95 mmHg at screening); history of stroke; severe asthma; hyperthyroidism; narrow-angle glaucoma; stenosing gastroduodenal ulcer; pyloroduodenal obstruction; symptomatic prostatic hypertrophy or bladder neck obstruction; uncontrolled type I or type II diabetes, or a history of ketoacidosis, hyperglycemic coma, or severe hypoglycemia with loss of consciousness.","ALL","18 Years",{"count":20,"type":21},172,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants.\n\nThe Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \\[0.16-1.65\\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.",[27,28,29],"Alcohol Use Disorder","Depressive Sympotoms","Psilocybin","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":31,"type":34},{"date":37,"type":21},"2030-06",{"name":39,"class":40},"Centre Hospitalier Universitaire de Nīmes","OTHER",8,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100576111","descriptive-study-on-mri-contrast-of-acute-cerebral-hemorrhage-in-different-microangiopathies-100576111","NCT06781034","Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies","GADO-ICH","Inclusion Criteria:\n\n* Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;\n* Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.\n\nExclusion Criteria:\n\n* Patient refusing to participate",{"count":50,"type":21},128,"OBSERVATIONAL","Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.\n\nArterial contrast (\"spot sign\") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.\n\nAn equivalent marker has also been described in gadolinium-enhanced MRI.\n\nBy studying the radiological appearance of gadolinium \"spot signs\" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.",[54,55],"Cerebral Hemorrhage","Acute Lobar Haematoma",[57,58],"Cerebral haemorrhage","MRI","2026-06-29",{"date":33,"type":34},{"date":62,"type":34},"2025-02-03",{"date":64,"type":21},"2026-12",{"name":39,"class":40},1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":66},"100645356","performance-and-safety-of-the-antalgeek-thess-monitoring-medical-device-in-the-outpatient-management-of-acute-pain-and-postoperative-recovery-100645356","NCT07680998","Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery","Evaluation of the Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery - A Single-Center, Randomized, Controlled Proof-of-Concept Study.","TRACE","Inclusion Criteria:\n\n* Patients eligible for outpatient surgery.\n* Patients undergoing surgery likely to result in moderate to severe pain.\n* Patients available for a 3-month follow-up.\n* Patients who have provided their free and informed consent.\n* Patients who have signed the consent form.\n* Patients enrolled in or covered by a health insurance plan.\n\nExclusion Criteria:\n\n* Patients participating in an interventional RIPH study involving a drug or classified as Category 1.\n* Patients in an exclusion period determined by another study.\n* Patients under judicial protection, guardianship, or conservatorship.\n* Patients unable to express consent.\n* Patient for whom it is impossible to provide informed information.\n* Pregnant, laboring, or breastfeeding patients.",{"count":76,"type":21},150,[78],"NA","Acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year. Effective analgesic therapy in the first postoperative week is a key factor in reducing early postoperative morbidity and mortality. Poorly controlled APOP is a major risk factor for chronic postoperative pain. In France today, more and more patients undergo surgical procedures as outpatients. The challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either after outpatient surgery or after a prompt return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, postoperative pain management requires new strategies and\u002For organizational approaches to ensure high-quality pain management from the very start. The principle of analgesia for acute postoperative pain recommends: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy if maintenance therapy is insufficient, based on pain titration, using mild or strong oral opioids. Postoperative pain is the primary focus of postoperative care but the goal is also to improve postoperative recovery and enhance the patient's overall care. To date, there are no medical telemonitoring devices to support the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, enabling systematic postoperative screening for early and late warning signs of the risk of chronic pain. The Thess Monitoring device, which implements the ANTALGEEK® protocol, (TMA) was developed to optimize the efficiency of outpatient management of acute postoperative pain. It improves patients' adherence to maintenance treatment with adaptive, personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing). The aim is to ensure optimal pain resolution and improve early and late postoperative recovery during the first postoperative week. The TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain. By measuring pain scores daily during the first postoperative week, it identifies patients with a suboptimal pain trajectory who are at high risk of developing persistent pain beyond the third month. It also assesses warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway via the TMA system should make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.",[81,82],"Post Operative Pain","Chronic Pain",[81,84,85],"Pain Management","Monitoring","2026-06-26",{"date":88,"type":34},"2026-07-02",{"date":90,"type":34},"2025-12-01",{"date":92,"type":21},"2026-12-31",{"name":39,"class":40},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":51,"phases":4,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":66},"100644853","genomic-and-phenotypic-diversity-of-carbapenemase-producing-escherichia-coli-strains-circulating-in-southern-france-100644853","NCT07676513","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France.","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France. The \"CARBA-COLI\" Study","CARBACOLI","Inclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.\n\nExclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.",{"count":103,"type":21},163,"3 Years","Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line β-lactams, carbapenems, and frequent co-resistance to other classes of antibiotics, leading to increased morbidity and mortality. Their high epidemiogenic potential has enabled their global spread. In France, the incidence of Carbapenemase-producing Enterobacteriaceae is rising sharply, both in colonization and in infections. Parallel to this increase, Escherichia coli has become the most common Carbapenemase-producing Enterobacteriaceae (35% of strains in 2024, National Research Committee data), surpassing Klebsiella pneumoniae (24%).\n\nThe investigators hypothesize that the increase in the prevalence of carbapenemase-producing Echerichia coli is associated with a diversification of clones, enzymes, and their variants, and may pose a threefold threat: i) the spread of genes encoding carbapenemases within pathogenic extraintestinal Echerichia coli (ExPEC) pathogroups responsible for urinary tract infections and bacteremias, with a high risk of resistance spreading in the community, ii) the silent spread of Echerichia coli strains producing OXA-48 variants with reduced carbapenem hydrolytic activity, OXA-244 and OXA-484, which are not detected or poorly detected by conventionally used screening media and iii) the emergence of New Dehli Metallo-beta-lactamase (NDM) variants with high hydrolytic activity, such as NDM-5, within Echerichia coli clones possessing Penicillin-Binding Proteins (PLPs) with low affinity for antibiotics, leading to very high-level resistance and a therapeutic dead end in infected patients.",[107,108,109,110],"Antibiotic Resistance","Enterobacteriaceae Infections","Carbapenem-Resistant Enterobacteriaceae Infection","Colonization",[112,109,110,108],"Escherichia coli","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":34},{"date":117,"type":21},"2026-06-01",{"date":119,"type":21},"2028-06-01",{"name":39,"class":40},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":66},"100548051","identification-of-limiting-factors-in-the-locomotor-activity-of-individuals-with-lower-limb-amputation-100548051","NCT06415955","Identification of Limiting Factors in the Locomotor Activity of Individuals With Lower Limb Amputation:","Identification of Limiting Factors in the Locomotor Activity of Individuals With Lower Limb Amputation: Biomechanical, Physiological, Psychological.","AMPUTEEFACT","Inclusion Criteria:\n\n* Amputees in PRM hospitalisation at the CHU Nîmes RRL service University Rehabilitation Hospital in Le Grau du Roi.\n* All aetiologies: vascular, traumatic and septic.\n* Appropriate vascular equipment validated by PRM doctor.\n* Able to walk for 5 minutes on a treadmill.\n* Patient affiliated to or benefiting from a health insurance scheme.\n* Adult patient (\\>18 years) and under 80 years of age.\n\nExclusion Criteria:\n\n* Patients with uncorrected or untreated visual disorders.\n* Patients with major cognitive impairment (MOCA\\>23).\n* Patients with vestibular disorders.\n* Patient with uncontrolled epilepsy.\n* Patient with an unhealed amputation stump.\n* Weight \\> 135kg or \\\u003C 20kg\n* Patients with a FAC of 1 (i.e. patients requiring the firm and continuous assistance of another person to carry their weight and maintain their balance) or less.\n* Inability to properly adjust the sling to the corresponding body part due to:\n* Body shape\n* Colostomy bags\n* Skin lesions that cannot be adequately protected.\n* Any other reason that prevents the harness from being adjusted correctly and painlessly.","80 Years",{"count":131,"type":21},200,"The experience of amputation leads to a deterioration in quality of life, with undeniable somatic and functional repercussions. The result is a reduction in general mobility, increased metabolic energy requirements and a feeling of discomfort and pain. The rehabilitation objectives focus on improving, or at least maintaining, the range of movement of the lower limbs, strengthening the overall muscles, ensuring that the equipment is correctly adapted, re-training for physical exertion and working on balance and walking. The rehabilitation objectives focus on social inclusion with the equipment, to optimise the return home and promote social and professional reintegration, and therapeutic education. Factors influencing the postoperative resumption of walking in amputees have been identified as key elements in the success of rehabilitation management. These include maintaining joint range of motion before fitting any equipment, combating postoperative loss of muscle mass, managing cardiorespiratory deconditioning and, finally, resuming walking with the aid of equipment, taking account of fluctuating balance.\n\nThe literature shows that a change in the centre of gravity and postural instability, particularly when changing stance, are responsible for a greater risk of falls in lower-limb amputees. This asymmetry of gait, which is the cause of a greater risk of secondary joint degeneration, is found in both transtibial and transfemoral amputees. This alteration in balance has a direct influence on walking ability, and therefore calls for significant proprioceptive management in the rehabilitation programme. Gait analysis in lower-limb amputees therefore seems essential, both for the purposes of evaluating and monitoring rehabilitation treatment, and for prosthetic selection and adjustment. Three-dimensional assessment of walking in amputees, coupled with force platforms, is the test of choice for providing kinematic, kinetic and spatiotemporal data (motion capture).",[134],"Lower Limb Amputation","2026-06-23",{"date":114,"type":34},{"date":138,"type":34},"2025-03-15",{"date":64,"type":21},{"name":39,"class":40},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":162},"100548688","dynamic-balance-in-unilateral-transtibial-amputees-following-virtual-reality-versus-conventional-rehabilitation-100548688","NCT06424249","Dynamic Balance in Unilateral Transtibial Amputees Following Virtual Reality Versus Conventional Rehabilitation","EQUIL-ARC","Inclusion Criteria:\n\n* Unilateral transtibial amputees in hospitalized in the rehabilitation of the musculoskeletal system service\n* All etiologies: vascular, traumatic and septic.\n* Adapted vascular equipment validated by physician.\n* Able to walk for 5 minutes on a treadmill without technical assistance.\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study or one involving a drug or medical device, or is in a period of exclusion determined by a previous study\n* Patient already included in the present study.\n* The subject refuses to or is unable to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Patients with uncorrected or untreated visual disorders.\n* Patients with major cognitive disorders (MOCA\\>23).\n* Patients with vestibular disorders.\n* Patient with uncontrolled epilepsy.\n* Patient with an unhealed amputation stump.\n* Patients weighing \\> 135kg or \\\u003C 20kg.\n* Patients with a functional ambulation category of 1 (i.e. patients requiring the firm, continuous assistance of another person to carry their weight and maintain their balance) or less.\n* Patients with medication affecting exercise tolerance,\n* Patients with sensory impairments\n* Patients with significantly reduced bone density\n* Patients for whom it is impossible to correctly adjust the harness to the corresponding body part due to:\n\n  * Body shape\n  * Colostomy bags\n  * Skin lesions that cannot be adequately protected.\n  * Any other reason that prevents proper, pain-free adjustment of the sling.\n* Pregnant, parturient or breast-feeding patients.\n* Appearance of a stump wound during the study requiring discharge.\n* Patient with more than 50% absenteeism from rehabilitation sessions.\n* Patient requiring a new prosthesis insert.\n* Patient with a serious adverse event affecting dynamic balance rehabilitation.",{"count":149,"type":21},20,[78],"Amputation causes somatic and psychological damage. Prognostic factors for postoperative gait recovery include the need for proprioceptive re-education for dynamic balance. Improved gait patterns and use of the prosthesis contribute to an overall improvement in the amputee's autonomy. Virtual reality coupled with movement analysis allows personalization of treatment with objective assessment of progress.\n\nThe study authors hypothesize that a virtual reality protocol for the dynamic balance of a unilateral transtibial amputee in initial rehabilitation will improve the dynamic balance assessment criteria compared with a conventional rehabilitation protocol.",[153,154,155],"Amputees \u002F Rehabilitation","Virtual Reality","Postural Balance",{"date":157,"type":34},"2026-06-25",{"date":159,"type":34},"2024-10-14",{"date":64,"type":21},{"name":39,"class":40},2,{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100586073","optimizing-the-care-pathway-of-febrile-children-via-capillary-c-reactive-protein-assay-in-primary-care-100586073","NCT06910631","Optimizing the Care Pathway of Febrile Children Via Capillary C-reactive Protein Assay in Primary Care","Optimisation du Parcours de Soins Des Enfants fébriles Par l'Utilisation de la CRP Capillaire en Soins Primaires : Protocole d'un Essai Multicentrique randomisé","CRP-CAP","Inclusion Criteria:\n\n* The patient must be a member or beneficiary of a health insurance plan\n* Children consulting primary health institutes with fever (temperature ≥ 38°C) requiring CRP testing:\n\n  * Fever \\> 12h in infants aged 3 to 6 months\n  * Fever ≥ 5 days in children over 6 months of age\n  * Fever \\>12h regardless of age, and at the time of consultation, the doctor is concerned about the child's general condition, the tolerance of the fever, or doubts about a bacterial focus (e.g. suspicion of pneumopathy, appendicitis, etc.).\n* No severity criteria necessitating immediate hospitalization\n* No bacterial infection whose diagnosis is exclusively clinical or identified by other means (e.g. purulent AOM, bacterial angina identified by RDT, etc.).\n* Child whose parents and child have been informed about the study, and at least one parent has given consent for their child's participation in the study.\n* Enrolment of the child according to their capacity of discernment (for children aged 12 and over, enrolment is essential).\n* Child affiliated to or benefiting from a health insurance scheme\n\nExclusion Criteria:\n\n* The subject is participating in a category 1 interventional study, or a study with drug or medical device\n* Premature infants under one year of age\n* Immunosuppression\n* Sunstroke\n* Chronic infection\n* Malignant pathology\n* Autoimmune pathology\n* Sickle cell disease\n* Child with a central catheter","3 Months","15 Years",{"count":174,"type":21},420,[78],"Fever is the leading reason for outpatient consultations among children aged 2 to 9 years. The main concern in fever is severe bacterial infection, particularly for younger children. History and clinical examination do not always differentiate viral infections from bacterial infection. In 20% of febrile children, no infectious focus is found after examination and additional tests are necessary. The first one is measuring C-reactive protein (CRP). The results are obtained in several hours on an outpatient basis, causing long delays before starting treatment and often requiring telephone calls or further consultations. Emergency room use is constantly increasing, generating growing tensions within healthcare facilities, yet a large number of visits are avoidable. Among children visiting the pediatric emergency room, parents reported being referred by their primary care physician in approximately 20% of cases for children aged 1 to 5 years and in 30% of cases for children under one year old. The use of capillary medical device to measure CRP in primary care could reduce this referral rate and help relieve overcrowding in emergency rooms, as well as unscheduled consultation centers and medical analysis laboratories. This would result in a streamlined care pathway, saving time for both physicians and patients, as well as reducing the cost of care for the healthcare system.",[178],"Fever",[180],"C-reactive protein","2026-06-19",{"date":135,"type":34},{"date":184,"type":34},"2025-09-15",{"date":186,"type":21},"2027-06",{"name":39,"class":40},37,{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":197,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":66},"100527453","prognostic-role-of-inhibitor-of-apoptosis-protein-overexpression-on-recurrence-rate-in-cervical-cancer-100527453","NCT06147960","Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer","Evaluation of the Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on the 24-month Recurrence Rate in Locally Advanced Cervical Cancer","EPIcol","Inclusion Criteria:\n\n* Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification).\n* Patients aged ≥ 18 years.\n* Patients with a minimum of 2 years post-treatment follow-up.\n* Patients for whom the initial biopsy specimen (before treatment) is available.\n* Patients who have not indicated that they do not wish to participate in the study.\n* Patients affiliated to or benefiting from a health insurance scheme.\n\nExclusion Criteria:\n\n* Patients under court protection, guardianship or curatorship.","FEMALE",{"count":199,"type":21},180,"Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.",[202,203],"Cancer of Cervix","Apoptosis",[205,206,203],"Apoptosis inhibiting proteins","Cervical cancer","2026-06-18",{"date":209,"type":34},"2026-06-22",{"date":211,"type":34},"2024-09-26",{"date":213,"type":21},"2027-11",{"name":39,"class":40},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":223,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":66},"100628003","work-organization-and-gambling-addiction-100628003","NCT07455981","Work Organization and Gambling Addiction","Assessment of the Interaction Between Atypical Working Hours and\u002For Periods of Inactivity on Risky Gambling Practices Among Adults Working Under These Conditions.","OTAJ","Inclusion Criteria:\n\n* Employed patients\n* Patients who have gambled at least once during the year\n* Patients who are willing to participate in the survey.\n\nExclusion Criteria:\n\n* Patients who cannot read the French language",true,{"count":225,"type":21},1600,"Problem gambling (PG) is influenced by environmental, psychological, and socioeconomic factors, including impulsivity, depression, anxiety, and characteristics such as marital status, age, and educational level. In France, approximately 5% of adults are affected by PG. Workers with atypical schedules or periods of inactivity at work are at risk of developing problematic gambling behavior. Stress, burnout, and boredom at work can exacerbate these risks. Working atypical hours, such as night shifts, is linked to mental health disorders such as depression and anxiety, which may increase the risk of PG. However, there is a lack of research on the impact of atypical schedules and periods of inactivity on PG. This research will explore the association between work schedules, periods of inactivity, and PG, particularly among workers who may be influenced by gambling norms and the specific characteristics of their jobs.",[228,229],"Problem Gambling","Addiction Gambling",[231,232,233,234,235],"Gambling","Impulsivity","Boredom","Addiction behavior","Shift work schedule","2026-06-17",{"date":207,"type":34},{"date":33,"type":21},{"date":240,"type":21},"2026-12-01",{"name":39,"class":40},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":162},"100615428","monthly-monitoring-of-plasma-nfl-in-treated-relapsing-remitting-multiple-sclerosis-to-detect-persistent-infraclinical-disease-activity-100615428","NCT07292480","Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity","Monthly Monitoring of Plasma NfL in Treated RRMS to Detect Persistent Infraclinical Disease Activity","MoMo-NfL","Inclusion Criteria:\n\n* Patient with RRMS according to 2024 McDonald's criteria.\n* Less than 10 years from disease onset.\n* Active RRMS (EDA) observed during the last 24 months: relapse and\u002For NELs and\u002For CELs as compared to a previous MRI performed within 24 months (± 3 months).\n* Current MET (IFN, GA, TE, fumarates) for less than 24 months.\n* Standard MRI follow-up scan performed less than 90 days before inclusion.\n* Clinically stable disease for at least 30 days.\n* Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL.\n* For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial.\n* Patients able to adhere to the study visit schedule.\n* Patient must have signed and given the consent.\n* Patient affiliated or beneficiary of a health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman.\n* Patient unable to perform brain and\u002For spinal cord MRI scans.\n* Patient not willing to perform monthly blood punctures.\n* Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone).\n* Patient with a relapse within 6 months before inclusion.\n* Patient with CELs within 3 months before inclusion.\n* Patient with progressive MS.\n* Patient unable to sign the consent.\n* It is impossible to correctly inform the patient.\n* Patient already participating in therapeutic research or in an exclusion period. The exclusion period corresponds to five half-lives (t1\u002F2) of the experimental drug.\n* Patient under judicial protection, or is an adult under guardianship.\n* Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control for the duration of the trial.","55 Years",{"count":252,"type":21},84,[78],"Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2\u002FFLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response. However, some studies have suggested the deposition of gadolinium-based contrast agents in the basal ganglia and dentate nucleus of patients who underwent serial MRI acquisitions. Although significant clinical consequences of these deposits have not been demonstrated, further studies are required to better understand the potential long-term biological and clinical effects of gadolinium administration. To circumvent this potential risk, several recommendations suggested avoiding unnecessary use of gadolinium for follow-up scans. New sequences are also developed to replace gadolinium injection for the detection of active lesions. Moreover, MRI remains costly and time-consuming. In addition, systematic yearly MRI monitoring is not adapted to detect silent active lesions. This can delay identification of treatment failure and increase the risk of relapses and disability worsening, especially in the context of escalation therapy.\n\nTherefore, biological markers could allow more frequent analysis of disease activity and detect treatment failure earlier than classical clinical and MRI monitoring. Their use would greatly help clinicians to switch for high efficacy treatments (HET) and avoid potential relapses.\n\nMeasurement of a structural axonal protein, neurofilament, in serum or plasma has shown promise as a marker of neuroaxonal injury and a measure of treatment response. In MS, cerebrospinal fluid (CSF) neurofilament-light chain (NfL) is also increased and is positively associated with MRI lesion load and disability scores and is a marker of treatment response.\n\nWThe study authors hypothesize that monthly plasma neurofilament-light chain (pNfL) monitoring can sensitively highlight subclinical (radiological disease activity) RDA by performing early MRI scans to confirm EDA and lead to timely treatment escalation.\n\nThe main objective of this study is to compare the time to EDA in both arms (monthly pNfL monitoring vs. standard care with regular MRI scans), in patients with EDA.",[256],"Multiple Sclerosis (MS) - Relapsing-remitting",[258],"Biomarker",{"date":207,"type":34},{"date":261,"type":34},"2025-12-12",{"date":263,"type":21},"2030-12",{"name":39,"class":40},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":280,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":66},"100608396","determining-the-prevalence-of-muir-torre-syndrome-in-patients-with-lynch-syndrome-100608396","NCT07201012","Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome","SMT-SL","Inclusion Criteria:\n\n* Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).\n* Patient followed at Nîmes University Hospital.\n* Patient having given free and informed consent.\n* Person affiliated to or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Person under court protection, guardianship or curatorship.\n* A person who is unable to give consent.\n* Person for whom it is impossible to give informed information.",{"count":76,"type":21},[78],"The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.",[276,277,278,279],"Basal Cell Carcinoma of Skin, Site Unspecified","Epidermoid Carcinoma","Lynch Syndrome","Muir-Torre Syndrome",[281,282,283],"Carcinoma","Screening","Skin cancer",{"date":209,"type":34},{"date":286,"type":34},"2026-03-13",{"date":288,"type":21},"2027-12",{"name":39,"class":40},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":223,"sex":17,"minAge":18,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":66},"100548256","variations-in-the-hemostatic-system-induced-by-a-standardized-walking-test-100548256","NCT06418633","Variations in the Hemostatic System Induced by a Standardized Walking Test","Variations in the Hemostatic System Induced by a Standardized Walking Test: Controls vs. Cases With a History of Non-anticoagulated Venous Thromboembolic Disease","FAST&THROMBIN","Inclusion Criteria:\n\n* Inclusion criteria common to both groups :\n* Patients who have given written informed consent.\n* Patients who are affiliated to or beneficiaries of a social security scheme.\n\nInclusion criteria specific to the Patient Group:\n\n* Patients with a personal history of provoked venous thromboembolism, venous thrombosis and\u002For pulmonary embolism, with the last attack dating back to more than 6 months, and whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis.\n\nDefinition of provoked venous thromboembolism : The clinical criteria used to classify venous thromboembolism as provoked are :\n\n* First year of combined oestrogen-progestogen oral contraception, or contraception using an oestrogen-impregnated vaginal ring or transcutaneous synthetic oestrogen patch.\n* Hormonal stimulation for oocyte retrieval\n* Pregnancy and 6 weeks post-partum\n* Surgery\n* Trauma\n* Immobilisation in plaster or splint\n* Outbreak of acute infectious disease\n* Acute flare-up of inflammatory disease\n* Prolonged air travel lasting at least 4 hours\n* Prolonged strict bed rest lasting at least 3 consecutive days.\n\nInclusion criteria specific to the Control Group:\n\n* Subjects with no personal history of venous thromboembolism\n* Subjects with no family history of venous thromboembolism in first-degree relatives\n* Subjects of the same sex and age with a tolerance of +\u002F- 5 years in relation to the matched case.\n\nExclusion Criteria:\n\n* Patients who are physically unable to perform the 60-minute walking test, for any reason, in particular cardiovascular contraindications to exercise (recent acute coronary syndrome unstable angina, rhythm disorders, tight aortic stenosis, cardiac heart failure, acute myocarditis, pericarditis or endocarditis endocarditis, poorly controlled hypertension, pre-stress blood pressure \\> 200\u002F110 mmHg, recent stroke or transient ischemic attack).\n* Patients on anticoagulant or antithrombotic treatment, ongoing or discontinued within the last month.\n* Patients treated for pulmonary embolism who remain dyspneic after anticoagulant treatment and requiring a work-up for pulmonary hypertension.\n* Last surgery dating back to less than 3 months.\n* Known chronic morbidities: diabetes mellitus, chronic inflammatory or infectious disease, heart failure, renal insufficiency, hepatic insufficiency or arterial thrombosis dating back to less than 3 months.\n* For women: treatment containing synthetic or natural estrogen, in progress or discontinued for less than a month\n* Pregnancy within the last year.\n* Difficult venous access.\n* Regular practice of an intensive sporting\u002Fphysical activity, such as running, tennis, cycling etc. of more than 3 hours per week.","65 Years",{"count":300,"type":21},94,[78],"Two groups of patients will be compared: One group of patients with a history of venous thromboembolic disease and one group without. Both groups will be subjected to a walking test and with electrocardiogram measurements and blood tests.",[304],"Venous Thromboembolism",[306],"Physical exercise",{"date":209,"type":34},{"date":309,"type":34},"2025-02-11",{"date":311,"type":21},"2030-04-01",{"name":39,"class":40},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":172,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":66},"100435239","efficacy-of-patient-management-for-lymphoma-diagnosed-at-nimes-university-hospital-from-1999-to-2018-dvr-lym-nim-100435239","NCT04947618","Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim","Evaluation of the Efficacy of Management of Patients With Lymphomas Diagnosed at Nimes University Hospital Over 20 Years (1999-2018) Under Real-life Circumstances","DVR-Lym-Nim","Inclusion Criteria:\n\n* Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.\n\nExclusion Criteria:\n\n* Patients aged 18 or over who have expressed their desire not to take part in the study.\n* Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study.\n* Patients under legal guardianship.",{"count":322,"type":21},400,"Observation of a cohort of 400 patients with different types of lymphomas.",[325],"Lymphoma, Malignant",[327,328,329,330,331,332,333,334],"Mantle-Cell","Follicular","Hodgkin","T-cell","Primitive Cerebral","Marginal Zone","Waldenström's macroglobulinemia","lymphoma","2026-06-15",{"date":236,"type":34},{"date":338,"type":34},"2024-01-22",{"date":340,"type":21},"2027-01-31",{"name":39,"class":40},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":66},"100409615","situation-and-evolution-of-the-misuse-of-alcohol-and-other-addictive-behaviors-in-obese-patients-being-managed-at-nmes-university-hospital-100409615","NCT04613791","Situation and Evolution of the Misuse of Alcohol and Other Addictive Behaviors in Obese Patients Being Managed at Nîmes University Hospital","ADOB","* Patient being managed for the first time at Nîmes University Hospital Obesity Clinic ( complete hospitalization, outpatients' or consultation).\n* Patient being managed for obesity defined by a body mass index (BMI) of 30 kg.m-² or over\n* Patient affiliated to or covered by a health insurance scheme.\n* Adult patient (≥ 18 years).\n\nExclusion Criteria:\n\n* Patient with psychiatric disorder reducing capacity for comprehension.\n* Patient in an exclusion period determined by another study.\n* Patient under legal guardianship, tutorship or curatorship.\n* Patient to whom it is impossible to give clear information\n* Patient who is pregnant, about to give birth or breastfeeding.",{"count":350,"type":21},800,"Obesity is a multifactorial pathology in which external (lifestyle, environment) and internal (psychological or biological, especially genetic) factors are involved. These are responsible for a positive energy balance. One of the external factors that can intervene in the genesis of obesity is the existence of eating disorders: bulimic hyperphagia. Some teams consider bulimic hyperphagia as a form of addiction. After bariatric surgery, the appearance of new addictions has been observed.\n\nIn connection with Pr Perney's addictology department, the investigators have observed that some patients under treatment for obesity at the endocrinology department subsequently developed other addictions, in particular misuse of alcohol.\n\nThe hypotheses of this research are :\n\nThere appears to be a transfer from eating disorders to substance misuse addiction in post-treatment of obesity, particularly in patients who have undergone bariatric surgery.\n\nThe misuse of addictive substances most concerned by this transfer of addiction in the post-treatment of obesity, particularly after bariatric surgery, seems to be the misuse of alcohol.\n\nThis will be the first French cohort study on addictive behaviors in patients undergoing bariatric surgery and the first international study including non-operated obese patients benefiting from medical care alone. This study will improve the multidisciplinary management of these patients by integrating addictologists.",[353],"Obesity",{"date":355,"type":34},"2026-06-16",{"date":357,"type":34},"2021-02-16",{"date":359,"type":21},"2026-12-15",{"name":39,"class":40},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":66},"100390749","variability-of-heart-rate-as-a-marker-of-complication-of-colorectal-surgery-100390749","NCT04367987","Variability of Heart Rate as a Marker of Complication of Colorectal Surgery","VFC COLORECTAL","Inclusion Criteria:\n\n* Patients operated for a scheduled colorectal resection due to cancer, diverticulitis, or Chronic Inflammatory Bowel Disease,\n* American Society of Anesthesiologists score 1-2\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* Patient taking antidepressants, antipsychotics, antihypertensive beta blocker type, anti-arythmic or oral contraception\n* Uncontrolled diabetes or associated with a neuropathy\n* Arrhythmias and conduction disturbances, , coronaropathy and heart failure, kidney failure\n* Neuropathies\n* Pacemaker or defibrillator\n* The subject is participating in another interventional study, or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship",{"count":369,"type":21},117,"Heart rate variability reflects the autonomic nervous system on the intrinsic activity of sinus node cells. Sympathetic hyperactivity is an adaptation to stress, while parasympathetic hyperactivity is present at rest. Thus, any variability in the heart frequency rate reflects variations in sympathetic and parasympathetic components in the autonomic nervous system. Failure to return to normal or a reduction in the variability of the heart rate in the postoperative period is correlated with complications in colorectal surgery.",[372],"Surgery--Complications",{"date":355,"type":34},{"date":375,"type":34},"2020-06-17",{"date":186,"type":21},{"name":39,"class":40},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":66},"100612658","feasibility-study-of-a-transition-pathway-at-discharge-from-full-hospitalization-in-oncology-100612658","NCT07256444","Feasibility Study of a Transition Pathway at Discharge From Full Hospitalization in Oncology","Etude de faisabilité d'un Parcours de Transition à la Sortie d'Hospitalisation complète en Oncologie - Etude Pilote Monocentrique","PATROL","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* Adult patient hospitalized in an oncology unit for at least 48 hours.\n* Patient capable of using a connected device, in possession of a smartphone or tablet, and with an internet connection at home.\n* Patient discharged from hospital to go home.\n\nExclusion Criteria:\n\n* The patient is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Patient considered to be at the end of life.\n* Patient unable to read and understand French\n* Patient discharged from hospitalization to a home care facility\n* Patient having been hospitalized in a full-time inpatient setting for a scheduled procedure (chemotherapy or interventional procedure)\n* Pregnant, parturient, or breastfeeding",{"count":387,"type":21},50,"Patient reported outcomes (PRO) measure the health status directly reported by the patients, without external interpretation, generally collected using self-questionnaires, including online tools (ePRO). This approach is useful in early detection of signs of relapse, with reduced anxiety, improved quality of life and survival, and reduced readmissions to emergency departments in patients with advanced cancer. In the current context where hospitalization is increasingly short, the transition from hospital to home is a critical moment that poses a significant safety challenge Patient follow-up strategies help patients return home, particularly in surgery, with telephone calls from a nurse the day after or several days after discharge. In oncology, telephone calls from the pharmacist 3 days after discharge from hospital helped to identify undesirable effects of treatments. In general medicine, these calls have led to improved patient satisfaction, reduced use of emergency departments and the resolution of drug-related problems, but are costly. The introduction of post-hospitalization ePRO monitoring in oncology could ensure effective follow-up while keeping costs under control. A coordinating nurse could manage this process and play a crucial role in accompanying patients when they return home.\n\nThe study authors aimed to evaluate the feasibility of a transitional nurse consultation and ePRO follow-up on discharge from full hospitalization in oncology in this population of frail and elderly patients.",[390],"Cancer","2026-06-05",{"date":393,"type":34},"2026-06-09",{"date":395,"type":34},"2026-06-02",{"date":397,"type":21},"2028-12",{"name":39,"class":40},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":409,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":162},"100611121","phase-1-labile-iron-removal-by-adding-the-iron-chelator-mex-cd1-to-dialysate-in-sepsis-associated-acute-kidney-injury-100611121","NCT07236463","Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury","Performance and Safety of Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate During Continuous Veno-venous Hemodialysis for Sepsis-associated AKI: Protocol for a Phase I-II Randomized Crossover Pilot Study.","IRON-IC","Inclusion Criteria:\n\n* Adult patients (≥18 years) admitted to ICU with sepsis-associated AKI requiring CRRT\n* Sepsis defined according to SEPSIS-3 criteria (suspected\u002Fdocumented infection with organ dysfunction indicated by ≥2-point increase in SOFA \\[Sequential Organ Failure Assessment\\] score)\n* AKI Stage 3 per KDIGO (Kidney Disease: Improving Global Outcomes) criteria: acute rise in serum creatinine ≥3 times baseline or serum creatinine ≥4 mg\u002FdL or urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours or anuria (urine output \\\u003C100ml) for ≥12 hours\n* Indications for CRRT: refractory hyperkalemia (\\>6 mmol\u002FL) or refractory metabolic acidosis (pH \\\u003C 7.20) or acute pulmonary edema unresponsive to medical management or urine output \\\u003C0.3 ml\u002Fkg\u002Fhour or anuria (urine output \\\u003C100ml) persistent for 48 hours and refractory to medical treatment\n* Informed consent obtained from patient or legal representative\n* Affiliated with or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* Known shellfish allergy\n* Moribund status with life expectancy too low to benefit\n* Concurrent participation in another interventional study\n* Exclusion period defined by another study\n* Under legal protection (guardianship or curatorship)\n* Inability to obtain informed consent from patient or representative\n* Pregnant, parturient, or breastfeeding women",{"count":408,"type":21},14,[410,411],"PHASE1","PHASE2","The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the intensive care unit (ICU). The main questions it aims to answer are:\n\nDoes adding MEX-CD1 to the dialysis fluid increase the amount of iron removed during dialysis? Is using MEX-CD1 in dialysis fluid safe for patients?\n\nParticipants will:\n\nBe adults in the ICU with sepsis-associated AKI who need continuous dialysis (renal replacement therapy) Receive two 24-hour dialysis sessions: one with standard dialysis fluid and one with dialysis fluid containing MEX-CD1 Serve as their own control, meaning they will receive both treatments\n\nResearchers will measure:\n\nThe amount of iron removed in the dialysis waste fluid (primary outcome) Blood levels of iron Changes in other trace elements Markers of inflammation and oxidative stress Safety outcomes up to 28 days after treatment This is a pilot study being done at a single hospital in France.",[414,415],"Acute Kidney Injury","Sepsis",[414,415,417,418,419],"Continuous Renal Replacement Therapy","Iron Chelating Agents","Intensive Care Unit","2026-06-04",{"date":391,"type":34},{"date":420,"type":34},{"date":424,"type":21},"2028-06",{"name":39,"class":40},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":443,"locationsCount":4},"100638707","assessment-of-sevoflurane-consumption-during-general-anesthesia-with-a-low-fresh-gas-flow-rate-of-03-lmin-100638707","NCT07628231","Assessment of Sevoflurane Consumption During General Anesthesia With a Low Fresh Gas Flow Rate of 0.3 L\u002FMin","FGF 03","Inclusion Criteria:\n\n* Adult patients undergoing surgery under general anesthesia with mechanical ventilation\n\n  * Connected to a ventilator linked to the Carestaion software\n  * No refusal as indicated by a letter of consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Minor patients",{"count":434,"type":21},30,"Driven by industry demands and the need for anesthesia that consumes fewer resources (\"green anesthesia\"), manufacturers of anesthesia ventilators have developed closed-circuit ventilators. In a closed-circuit system, during the exhalation phase, gases are not released outside the ventilator into the atmosphere but are injected into the inspiratory limb of the circuit after being warmed and having CO2 removed. It is a closed loop. However, the loop is not completely closed because a very small stream of air is additionally injected into the inspiratory limb to limit the risk of hypoxia. This small stream of air is called \"Fresh Gas Flow\" or FGF.\n\nTo optimize this closed-loop recirculation, manufacturers have designed machines capable of minimizing the fresh gas flow. In the 2000s, machines operated with FGFs of 2 L\u002Fmin, dropping to flows as low as 0.5 L\u002Fmin by 2010. This low-flow regime allows for an 80% reduction in halogenated gas (sevoflurane) consumption while maintaining the same efficiency. Recently, even more sophisticated machines have been designed with FGFs of 0.3 L\u002Fmin. Some of these new machines will be commercially available on a large scale in 2026. As part of an industrial partnership, the Nîmes University Hospital has validated the post-CE marking of these machines for certain manufacturers (including General Electric); the post-CE marking allows the manufacturer to have access to usage data Given that this product has only recently been introduced to the market, very little data has been published on the use of sevoflurane in daily practice at very low FGF flow rates (0.3 to 0.5 L\u002Fmin).\n\nFor the past four months, the Nîmes University Hospital has had two CE-marked machines (GE, CS 850) capable of ventilating at flow rates of 0.3 L\u002Fmin. These machines are connected to software (Carestation Insight) that allows all anonymized ventilator data to be recorded independently of the users. This software has been in continuous use in 12 operating rooms since 2024 within our institution and has been the subject of numerous publications (see Ref. 19). All ventilation and sevoflurane data are continuously recorded and stored in a secure, anonymous cloud (Ref. 19).\n\nThe objective of this retrospective study is to analyze the database of sevoflurane consumption derived from the Carestation Insight software for patients who underwent general anesthesia with ventilation at FGF flow rates of 0.3 L\u002Fmin and to compare these data with our database of patients under anesthesia at flow rates of 0.5 to 2 L\u002Fmin, also derived from this same cloud.",[437],"Anesthesia","2026-06-03",{"date":420,"type":34},{"date":441,"type":21},"2026-06",{"date":288,"type":21},{"name":39,"class":40},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":465},"100638910","phase-2-efficacy-of-botulinum-toxin-versus-placebo-on-pain-and-health-related-quality-of-life-of-patients-with-piriformis-muscle-syndrome-100638910","NCT07624045","Efficacy of Botulinum Toxin Versus Placebo on Pain and Health Related Quality of Life of Patients With Piriformis Muscle Syndrome","A Phase IIb, Randomized, Double-blind, Multicenter Study Evaluating the Efficacy of Botulinum Toxin Versus Placebo on Pain and Health Related Quality of Life of Patients With Piriformis Muscle Syndrome","PiriTox","Inclusion Criteria:\n\n* Objective clinical diagnosis of unilateral piriformis syndrome for at least 3 months (as assessed by Clinical Scoring System for the Diagnosis of Piriformis Muscle Syndrome: score of 8 or greater\n* Absence of herniated lumbar disc which can explain radiating pain (MRI or computed tomography (CT) of the lumbar spine)\n* Patients not responding to conventional care (physiotherapy, muscle relaxants, analgesics)\n* Baseline sciatic pain intensity of at least 4 points on visual analog scale\n* Provision of written informed consent\n* Patients affiliated to social security system (health insurance coverage).\n\nExclusion Criteria:\n\n* Bilateral piriformis muscle syndrome.\n* History of piriformis syndrome surgery.\n* History of botulinum toxin administration.\n* Any treatment (general or local) likely to interfere with botulinum toxin or evaluation of the primary endpoint (Corticosteroids, aminoglycosides).\n* Corticosteroids in the past 3 weeks.\n* Signs of severe fibrosis (on MRI or CT) of the piriformis muscle.\n* Other causes of sciatic pain (lumbar root compression, inflammatory, infectious or neoplasic pelvic disease, particularly for inflammatory sacroiliac pain).\n* Hip prosthesis on the same side as piriformis syndrome; knee prosthesis is tolerated.\n* Contraindication to BT injection:\n* History of intolerance, hypersensitivity or known allergy to any botulinum toxin product or excipients;\n* Patients with myasthenia gravis or other diseases of the neuromuscular junction;\n* Patients with Lambert-Eaton Syndrome;\n* Patients with neurological disorders such as dysphagia, swallowing disorders or aspiration pneumonia;\n* Current infection at the proposed injection site;\n* Long-term anticoagulant therapy ;\n* Antibiotics and vaccination are prohibited for 15 days before and after BT injection\n* Pregnant or breastfeeding women. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant must use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, method of double-barrier contraceptive patches). The contraception should be maintained throughout the study.\n* Patients unable to complete the patient diary.\n* Inability to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with inclusion in the study.\n* Patients with legal disability or limited legal capacity.\n* Patients judged as noncompliant.",{"count":453,"type":21},108,[411],"Piriformis muscle syndrome (PMS) is characterized by symptoms caused by compression or irritation of the sciatic nerve by the piriformis muscle as it exits the sciatic notch. PMS commonly evokes the symptoms of sciatica and is likely underdisagnosed. Patients who experience pain related to piriformis syndrome will complain of aggravated pain after prolonged periods of sitting or upon rising from a seated position. Around 98% of patients evoke positional buttock pain, especially during prolonged sitting (car journeys, for example). This is less true for sciatic pain radiation, which is still found in 63% of cases, systematically associated with the notion of buttock pain. Treatments for PMS aim to reduce or eliminate sciatic pain and also control buttock pain. Reducing these pains can improve the physical condition and emotional state of the patient. Several approaches have been proposed including physical therapy (massage-physiotherapy, self-rehabilitation techniques) combined with the use of anti-inflammatory drugs, analgesics and muscle relaxants to reduce inflammation, spasm and pain. Many patients do not respond to conventional care. Surgery may be considered only in those cases who do not improve with conservative therapy or injections. However, decompressive surgery is an invasive treatment, indicated in case of complete failure of all medical strategies, with physical and functional consequences. In recent years, several published studies showed the use of botulinum toxin (BT) injection as a new therapeutic option to reduce buttock and sciatic pain induced by PMS. The study team previously observed the efficacy of BT\u002FA1 administration into the piriformis muscle in patients who were previously treated with medication and rehabilitation protocols with no pain improvement. Pain relief was considered as \"very good\" or \"good\" for 77% of the patients, \"average\" for 7.4% and \"poor\" for 15.6%. No adverse events were reported. More recently, Fishman and colleagues reported the results of a randomized, double-blind, controlled study including 56 patients and comparing physical therapy, incobotulinum toxin A and placebo. Data are sparse concerning BT injection for PMS and no multicenter randomized clinical trial have been performed. Two out of three randomized trials (Fishman 2004, 2017) are based on highly selected patients (3 standard deviations or more beyond on the prolongation of the posterior tibial or fibular nerve H-reflex in FAIR test). Therefore, BT efficacy may be overestimated and remains to be evaluated among unselected PMS patients, regardless of analgesic treatments or physical therapy. Finally, no randomized studies have reported the heatlh-related quality of life of PMS patients.",[457],"Piriformis Muscle Syndrome","2026-05-29",{"date":438,"type":34},{"date":461,"type":21},"2026-07",{"date":463,"type":21},"2029-01",{"name":39,"class":40},7,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":488,"leadSponsor":490,"locationsCount":66},"100623966","evaluation-of-the-short-term-effectiveness-of-spinal-manipulation-to-treat-acute-and-subacute-low-back-pain-100623966","NCT07403500","Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain.","Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. An Open-label Randomized Controlled Multicenter Trial.","MeLoPe","Inclusion Criteria:\n\n* Patients seeking treatment for low back pain present for less than 3 months, with an average intensity greater than 50 on a visual analog scale of 0-100 in the previous 48 hours.\n* Patients able to complete online questionnaires.\n* Patients who have given their free and informed consent.\n* Patients who are affiliated with or beneficiaries of a health insurance plan.\n\nExclusion Criteria:\n\n* Patients with a history of back surgery, undergoing corticosteroid or morphine treatment, with acute or chronic inflammatory diseases, with psychiatric illness, or with low back pain lasting more than 3 months.\n* Patients who have already undergone spinal manipulation for low back pain with the investigator.\n* Patients participating or having participated in a therapeutic or drug study in the 3 months prior to their inclusion in this protocol.\n* Patients in a period of exclusion determined by another study.\n* Patients under legal protection, guardianship, or conservatorship.\n* Patients unable to give their consent.\n* Patients for whom it is impossible to provide informed consent.\n* Pregnant or breastfeeding patients.",{"count":475,"type":21},416,[78],"Low back pain is the second most common reason for medical consultation in France and affects 60 to 80% of the working population. Patients with acute episodes of non-specific low back pain recover within 6 to 8 weeks, but recurrence is common and 7 to 10% of patients will experience persistent pain and disability for more than 3 months. Given their low efficacy and the risks associated with nonsteroidal anti-inflammatory drugs or opioids (nearly 60% of all opioids prescribed in the United States), the scientific literature does not support the use of pharmacological treatments. The international recommendations strongly suggest using non-pharmacological therapies, including physical exercise, rehabilitation, and spinal manipulation.Spinal manipulation (SM) is a common choice of therapy in primary care. In the patient's imagination \"getting manipulated when in pain leads to heavy use of these manual therapies in a medical (manual medicine and medical osteopathy) or non-medical setting (manual therapy, osteopathy, and chiropractic). However, the evidence of effectiveness is weak in the chronic phase (only in the short term) and contradictory for the acute or subacute phases of low back pain. Pain and function are improved at 6 weeks, but the results are not clinically relevant. There is a lack of evidence regarding efficacy because the trials on spinal manipulations are of poor quality. A meta-analysis has recently reported that SMs are associated with a very limited risk of harm, making them a reasonable treatment option. Therefore, it seems necessary to demonstrate the specific effect of MVs in order to justify their use in primary care, support their wider use around the world, and reinforce recommendations for non-pharmacological treatment of low back pain.",[479],"Back Pain Lower Back Chronic",[481,482,483,484],"Back","Pain","Chronic","Spinal manipulation","2026-05-28",{"date":458,"type":34},{"date":33,"type":21},{"date":489,"type":21},"2027-03-31",{"name":39,"class":40},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":500,"conditions":501,"keywords":504,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":66},"100499235","diagnostic-performance-of-the-resistance-index-ri-for-the-assessment-of-cerebral-vasoreactivity-in-transcranial-doppler-100499235","NCT05780619","Diagnostic Performance of the Resistance Index (RI) for the Assessment of Cerebral Vasoreactivity in Transcranial Doppler","REVACEIR","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* Stenosis ≥ 70% in diameter reduction in NASCET equivalent or occlusion of atheromatous origin of the cervical internal carotid artery, asymptomatic or symptomatic.\n* Presence of a temporal window sufficient to record the homolateral and contralateral middle cerebral artery.\n* Patient of legal age with free and informed consent.\n* Patient who has signed the consent form.\n* Patient affiliated or beneficiary of a health insurance plan.\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Contraindication to Acetazolamide Diamox® injection.\n* Absence of temporal acoustic window (non visualization of the cerebral parenchyma, no recordable intracranial vessel).\n* Insufficient temporal window (visualizable brain parenchyma, no recordable MCA)\n* Internal or common carotid artery stenosis ≥70% or occlusion, contralateral to the primary lesion.\n* Stenosis ≥50% of the middle cerebral artery homolateral or contralateral to the cervical lesion.\n* Patient in exclusion period determined by another study.\n* Patient under court protection, guardianship, or conservatorship.\n* Patient refusing to sign the consent form.\n* Patient unable to express his or her will (dementia, disturbed consciousness, etc.)\n* Patient for whom it is impossible to give informed information for health reasons or because of a language barrier.\n* Pregnant, parturient, or breastfeeding patient.",{"count":499,"type":21},77,"Routine revascularization of asymptomatic carotid stenosis is questionable as optimal medical therapy has significantly reduced the risk of stroke. Therefore, it is crucial to identify high-risk patients who may still benefit from carotid revascularization. In 2017, the ESC guidelines clarified the criteria associated with a high risk of stroke despite optimal treatment to consider a revascularization procedure, including altered cerebral vasoreactivity. However, cerebral vasoreactivity using transcranial Doppler ultrasound is reserved for qualified centers. It requires a technical platform and trained personnel, is time-consuming and generally not readily available.\n\nA simpler test is therefore necessary. The goal is to quickly and easily detect patients with normal vasoreactivity who do not benefit from the cerebral vasoreactivity test (reference standard) and to reserve the time-consuming cerebral vasoreactivity test for patients likely to have altered vasoreactivity.\n\nThe hypothesis of the study is that on a routine measure in transcranial echo-Doppler, the resistance index (RI), can predict the response to the cerebral vasoreactivity test. With this new test, it will be possible to select patients who do not benefit from pharmacological cerebral vasoreactivity testing (\"true negatives\"). Thus, the time-consuming cerebral vasoreactivity test will be reserved only for patients with a possibility of impaired vasoreactivity.",[502,503],"Stenosis","Occlusion",[505],"Acetazolamide",{"date":117,"type":34},{"date":508,"type":34},"2023-06-09",{"date":510,"type":21},"2029-06",{"name":39,"class":40},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":162},"100457028","effect-of-lumbar-surgery-on-complexity-during-a-walking-task-in-chronic-low-back-pain-100457028","NCT05231265","Effect of Lumbar Surgery on Complexity During a Walking Task in Chronic Low Back Pain","Effect of Lumbar Surgery on Complexity During a Walking Task in the Chronic Low Back Pain Patient","LOBAFRACS","Inclusion Criteria:\n\n* Patients with chronic low back pain requiring prosthesis or arthrodesis surgery on one or two levels\n* Subject affiliated or beneficiary of a health insurance plan.\n* The patient must have given their free and informed consent\n\nExclusion Criteria:\n\n* Patients with organic low back pain (infection, tumor, inflammatory rheumatism)\n* Patient with a neurological deficit (cauda equina syndrome or motor testing MRC \\\u003C 3 on a muscle group of the lower limbs)\n* Patient who has already undergone lumbar surgery (except single discectomy)\n* Patient with serious concomitant pathologies\n* Patients participating in a therapeutic study prohibiting participation in another study\n* Patient in an exclusion period from a different study\n* It is impossible to give the subject informed information\n* Patient is unable to express consent\n* The patient is under safeguard of justice or state guardianship\n* Patient is pregnant, parturient or breastfeeding",{"count":521,"type":21},32,"Lumbar surgery is the most common treatment for chronic disabling low back pain with degenerative disc disease. There are few elements to objectively evaluate the improvement of the motor control after surgery and the motor adaptation capacities of the patients.\n\nThe impact of lumbar surgery on complexity in this painful context has never been studied. Theoretically, the restriction of mobility imposed by lumbar surgery should limit the subject's adaptive capacities (of one or more lumbar segments) and thus reduce complexity. Nevertheless, improvement in pain intensity levels could allow the patient to find better motor adaptation capacities, necessary for a positive evolution in the long-term.\n\nThe aim of this study was to investigate the evolution of gait complexity in chronic low back pain patients pre- and post-surgery. If surgery improves the adaptability of walking through an antalgic benefit exceeding the induced stiffness, the complexity of walking should be superior after surgery.\n\nThis is a proof-of-concept study in which the study investigators hypothesize that measuring complexity by fractal analysis during a walking task will show the increase in gait complexity induced by lumbar surgery at 3 and 6 months after surgery.",[524],"Low Back Pain",{"date":117,"type":34},{"date":527,"type":34},"2023-10-16",{"date":529,"type":21},"2027-04",{"name":39,"class":40},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":223,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":547,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":162},"100523752","evaluation-of-concordance-between-exhaled-air-test-ebam-cov-and-rt-pcr-to-detect-sars-cov-2-100523752","NCT06099795","Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2","Evaluation of Concordance Between an Innovative Test on Exhaled Air (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 in Symptomatic Patients or Closed Contacts","eBAM_CoV","Inclusion Criteria:\n\n* Adult male or female patients over 18 years of age (≥)\n* Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening.\n\nExclusion Criteria:\n\n* Inability to understand the procedures to use the device\n* Patient participating in an another interventional study\n* Patient in exclusion period determined by another study\n* Patient under court protection or guardianship\n* Patient\u002Ftrusted person\u002Flegal representative\u002Ffamily member for whom it is impossible to give informed information.\n* Pregnant, parturient or breast-feeding patient",{"count":540,"type":21},250,[78],"During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins.\n\nTo overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the \"viral load\" with both quantitative and qualitative results, showing promise for early virus detection.\n\nThe researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.",[544,545,546],"SARS-CoV-2 Infection","COVID-19","Coronavirus",[548],"Diagnostic Test Kits","2026-05-22",{"date":551,"type":34},"2026-05-27",{"date":553,"type":34},"2025-01-01",{"date":288,"type":21},{"name":39,"class":40},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":66},"100544452","continuous-veno-venous-hemodialysis-and-continuous-veno-venous-hemodiafiltration-on-urea-reduction-rate-in-intensive-care-patient-100544452","NCT06369064","Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient","Comparison of the Effectiveness of Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patients With Acute Renal Injury : a Monocentric Controled Randomized Non Inferiority Open Labeled Study","CompEER","Inclusion criteria:\n\n* Adult patients hospitalized in ICU\n* Undergo RRT session because of AKI stage 3\n* At least one among criteria: pH \\\u003C 7,20 \u002F Blood urea \\> 30mM \u002F Fluid overload uncontrolled by with PaCO₂ \\\u003C 35 mmHg or mixed acidosis with PaCO₂ \\\u003C 50 mmHg.\n\n  * Oliguria lasting 72 hours or longer\n* Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization\n* Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation\n* Patient affiliated with Social Security.\n\nExclusion criteria:\n\n* End-stage chronic kidney disease on dialysis\n* Intoxication with a dialyzable toxin (lithium\n* Criteria for emergency dialysis initiation: hyperkaliemia \\>6,5mM with electrocardiographic signs\n* Medical contraindication to regional citrate: severe liver failure\n* Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding\n* Pregnant women, parturient or breast-feeding patient",{"count":565,"type":21},80,[78],"In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD).\n\nTo our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter).\n\nIn the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury.\n\nThe research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.",[414,417,419],[570,571,572],"continuous venovenous hemodiafiltration","continuous venovenous hemodialysis","urea reduction rate","2026-05-15",{"date":575,"type":34},"2026-05-18",{"date":577,"type":34},"2024-07-03",{"date":579,"type":21},"2028-08-15",{"name":39,"class":40},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":197,"minAge":18,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":590,"conditions":591,"keywords":595,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":66},"100576025","autophagyapoptosis-balance-in-placental-vascular-pathologies-100576025","NCT06779916","Autophagy\u002FApoptosis Balance in Placental Vascular Pathologies","Study of the Autophagy\u002FApoptosis Balance in Placental Vascular Pathologies","GROSSAUTOP-2","Inclusion Criteria:\n\n* Pregnant women developing a placental vascular complication (preeclampsia and\u002For intrauterine growth retardation), hospitalized and delivering at Nimes University Hospital.\n* Pregnant woman with free and informed consent.\n* Pregnant woman affiliated with and\u002For benefiting from a health insurance scheme.\n\nExclusion criteria:\n\n* Multiple pregnancy.\n* Presence of hypertension and\u002For proteinuria prior to pregnancy.\n* Participant in an interventional drug study.\n* Persons in a period of exclusion determined by another study.\n* Persons under court protection, guardianship or curatorship.\n* Persons unable to give consent.\n* Persons for whom it is impossible to give informed information.",{"count":387,"type":21},"Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies and can lead to maternal-fetal morbidity and mortality. It is essential to understand the cellular and molecular mechanisms of dysfunctions at the vascular-placental interface so that systemic vascular risk can be characterized and, ultimately, screened for, on the basis of new markers (targeted preventive management).\n\nDeregulated autophagy could be the starting point for cell death by apoptosis or necrosis leading to complications.\n\nThe pathophysiological mechanisms involved in trophoblast apoptosis are incompletely described. This project follows on from the GrossAuTop-1 study, which investigated the intra- and inter-individual variability of autophagy and apoptosis activities in women during pregnancy. The aim of this project is to study autophagy and apoptosis activities specifically in women developing a placental vascular complication during pregnancy.",[592,593,594],"Pregnancy Complications","Pre-Eclampsia","Growth Retardation, Intrauterine",[596,597,598,599,600],"trophoblasts","autophagy","apoptosis","placenta","pregnancy","2026-04-30",{"date":603,"type":34},"2026-05-06",{"date":605,"type":34},"2025-05-02",{"date":607,"type":21},"2029-05-01",{"name":39,"class":40},""]